natgillin/translations-raw huggingface dataset:
Due to the need of treatment, tacrolimus can be considered in pregnant women when there is no safer alternative and when the perceived
Ker je terapija potrebna, pride takrolimus v poštev tudi pri nosečnicah, če ni varnejše alternative in če pričakovana korist opravičuje možno tveganje za plod.
Lactation Human data demonstrate that tacrolimus is excreted into breast milk.
35 Podatki pri ljudeh kažejo, da se takrolimus izloča v materinem mleku.
Neoplasms benign, malignant and unspecified Patients receiving immunosuppressive therapy are at increased risk of developing malignancies.
Benigne, maligne, in neopredeljene neoplazme Bolnike, ki prejemajo imunosupresive, bolj ogroža pojav malignomov.
Metabolism and nutrition disorders very common:
Presnovne in prehranske motnje zelo pogosti: pogosti:
hyperglycaemic conditions, diabetes mellitus, hyperkalaemia
hiperglikemična stanja, diabetes mellitus, hiperkaliemija hipomagneziemija, hipofosfatemija, hipokaliemija, hipokalciemija, hiponatriemija, preobremenitev s tekočino, hiperurikemija, zmanjšanje apetita, anoreksija, metabolična acidoza, hiperlipidemija, hiperholesterolemija, hipertrigliceridemija, druge nepravilnosti elektrolitov
common:
občasni:
hypomagnesaemia, hypophosphataemia, hypokalaemia,
dehidracija, hipoproteinemija, hiperfosfatemija, hipoglikemija
hypocalcaemia,
Psihiatrične motnje zelo pogosti: pogosti:
hyponatraemia, fluid overload, hyperuricaemia, appetite decreased, anorexia,
nespečnost simptomi anksioznosti, zmedenost in dezorientiranost, depresija, potrtost, motnje razpoloženja, nočne more, halucinacije, duševne motnje
hyperlipidaemia,
psihotična motnja
hypercholesterolaemia,
Bolezni živčevja
uncommon:
zelo pogosti:
psychotic disorder
tremor, glavobol
Nervous system disorders very common: common:
36 pogosti:
tremor, headache seizures, disturbances in consciousness, paraesthesias and dysaesthesias, peripheral neuropathies, dizziness, writing impaired, nervous system disorders
konvulzije, motnje zavesti, parestezije in dizestezije, periferne nevropatije, omotica, moteno pisanje, bolezni živčevja
hepatic failure, bile duct stenosis
srbenje, izpuščaj, alopecije, akne, močnejše znojenje dermatitis, fotosenzibilnost
Skin and subcutaneous disorders common: uncommon: rare: very rare:
37 redki: zelo redki:
pruritus, rash, alopecias, acne, sweating increased dermatitis, photosensitivity toxic epidermal necrolysis (Lyell’ s syndrome) Stevens Johnson syndrome
toksična epidermalna nekroliza (Lyellov sindrom) Stevens- Johnsonov sindrom
Musculoskeletal and connective tissue disorders common: uncommon:
Bolezni mišično- skeletnega sistema in vezivnega tkiva pogosti: občasni:
arthralgia, muscle cramps, pain in limb, back pain joint disorders
artralgija, mišični krči, bolečine v okončini, bolečine v hrbtu sklepne motnje
Several cases of accidental overdosage have been reported; symptoms have included tremor, headache, nausea and vomiting, infections, urticaria, lethargy, increased blood urea nitrogen and elevated serum creatinine concentrations, and increase in alanine aminotransferase levels.
Med simptomi so bili tremor, glavobol, navzeja in bruhanje, okužbe, urtikarija, letargija, zvišanje sečnine v krvi, povečanje koncentracije kreatinina v serumu in zvišanje ravni alanin- aminotransferaze.
39 Pharmacotherapeutic group:
Farmakoterapevtska skupina:
Tacrolimus is a highly potent immunosuppressive agent and has proven activity in both in vitro and in vivo experiments.
38 Takrolimus je izredno močan imunosupresiv in njegovo delovanje je dokazano v poskusih in vitro in in vivo.
Tacrolimus suppresses T-cell activation and T-helper-cell dependent B-cell proliferation, as well as the formation of lymphokines (such as interleukins-2, -3, and γ -interferon) and the expression of the interleukin-2 receptor.
Takrolimus zavira aktivacijo celic T in od celic T pomagalk odvisno proliferacijo celic B, pa tudi nastajanje limfokinov (npr. interlevkina- 2, - 3 in γ- interferona) ter izraženje receptorja za interlevkin- 2.
Tacrolimus was started as continuous intravenous infusion at a dose of 0.01 to 0.03 mg/ kg/ day and oral tacrolimus was administered at a dose of 0.05 to 0.3 mg/ kg/ day.
Takrolimus je bil uveden kot stalna intravenska infuzija v odmerku od 0, 01 to 0, 03 mg/ kg/ dan, peroralni takrolimus pa je bil uporabljen v odmerku od 0, 05 to 0, 3 mg/ kg/ dan.
Freedom from acute rejection was higher in the tacrolimus group at 6 months (57.7% versus 45.8%) and at 1 year after lung transplantation (50% versus 33.3%) (Treede et al., J Heart Lung Transplant 2001; 20:511).
Enoletno preživetje v skupini s takrolimusom je bilo 73, 1% in v skupini s ciklosporinom 79, 2%, Delež bolnikov brez akutne zavrnitve je bil v skupini s takrolimusom večji po 6 mesecih (57, 7% v prim. s 45, 8%) in po 1 letu po presaditvi pljuč (50% v prim. s 33, 3%) (Treede et al., J Heart Lung Transplant 2001; 20: 511).
The initial oral per protocol dose of tacrolimus was 0.2 mg/ kg/ day with subsequent dose adjustments to target trough levels of 8 to
Uvodni peroralni odmerek takrolimusa po protokolu je bil 0, 2 mg/ kg/ dan z nadaljnjimi prilagoditvami odmerka tako, da je bila do 5. dne dosežena ciljna najmanjša koncentracija od 8 do 15 ng/ ml in po 6. mesecu od 5 do 10 ng/ ml.
Intestinal transplantation Published clinical experience from a single centre on the use of tacrolimus for primary treatment following intestinal transplantation showed that the actuarial survival rate of 155 patients (65 intestine alone, 75 liver and intestine, and 25 multivisceral) receiving tacrolimus and prednisone was 75% at 1 year, 54% at 5 years, and 42% at 10 years.
Presaditev črevesa Objavljene klinične izkušnje enega samega centra o uporabi takrolimusa pri primarnem zdravljenju po presaditvi črevesa kažejo, da je bilo aktuarsko preživetje 155 bolnikov (65 samo črevo, 75 jetra in črevo, 25 multivisceralno), ki so dobivali takrolimus in prednizon, po 1 letu 75%, po 5 letih 54% in po
A variety of innovations, such as techniques for early detection of Epstein-Barr (EBV) and CMV infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, lower initial tacrolimus doses with target trough levels of 10 to 15 ng/ ml, and most recently allograft irradiation were considered to have contributed to improved results in this indication over time (Abu- Elmagd et al., Ann Surg 2001; 234:404).
Domnevno so k izboljšanju rezultatov skozi čas pri tej indikaciji pripomogle različne inovacije, npr. postopki za zgodnje odkrivanje okužb z virusom Epstein- Barr (EBV) in CMV, prirast kostnega mozga, dodatna uporaba antagonista interlevkina- 2 daklizumaba, nižji začetni odmerki takrolimusa s ciljno najnižjo koncentracijo od 10 do 15 ng/ ml in, v najnovejšem času, obsevanje alotransplantata (Abu- Elmagd et al., Ann Surg 2001; 234: 404).
In a study of stable renal transplant patients who were administered< Invented name > immediately after a standard continental breakfast the effect on oral bioavailability was less pronounced.
V študiji stabilnih bolnikov po presaditvi ledvice, ki so zaužili < (Lastniško) ime zdravila > tik po običajnem zajtrku, je bil učinek na peroralno biološko uporabnost manj izrazit.
In plasma, tacrolimus is highly bound (> 98.8%) to plasma proteins, mainly to serum albumin and α -1-acid glycoprotein.
V plazmi je takrolimus v veliki meri (> č98, 8%) vezano na plazemske beljakovine, predvsem na serumski albumin in α- 1- kisli glikoprotein.
41 tacrolimus, or corticosteroid-induced increased metabolism are considered to be responsible for the higher clearance rates observed following transplantation.
Za hitrejši očistek po presaditvi so verjetno odgovorni dejavniki, kot sta nizek hematokrit in majhna koncentracija beljakovin, zaradi česar se poveča delež nevezanega takrolimusa, in s kortikosteroidi izzvano povečanje presnove.
The other metabolites have only weak or no immunosuppressive activity.
Ostali presnovki imajo le šibko imunosupresijsko
13.
41 9.
43 LABELLING AND PACKAGE LEAFLET
OZNAČEVANJE
LABELLING
44 PODATKI NA ZUNANJI OVOJNINI
CARTON 0.5 mg CAPSULES
ŠKATLA 0, 5 mg KAPSULE
Prograf and associated names (see Annex I) 0.5 mg hard capsules [See Annex I – To be completed nationally] Tacrolimus
Prograf in povezana imena (glejte Dodatek I) 0, 5 mg trde kapsule [Glejte Dodatek I - Izpolni država članica] Takrolimus
[To be completed nationally]
45 [Izpolni država članica]
BLISTER FOIL 0.5 mg CAPSULES
PRETISNI OMOT 0, 5 mg KAPSULE
48 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
47 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
ALUMINIUM WRAPPER 0.5 mg CAPSULES
ALUMINIJASTI OVITEK 0, 5 mg KAPSULE
Prograf and associated names (see Annex I) 0.5 mg hard capsules [See Annex I – To be completed nationally] Tacrolimus Oral use
Prograf in povezana imena (glejte Dodatek I) 0, 5 mg trde kapsule [Glejte Dodatek I - Izpolni država članica] Takrolimus Peroralna uporaba.
CARTON 1 mg CAPSULES
ŠKATLA 1 mg KAPSULE
Prograf and associated names (see Annex I) 1 mg hard capsules [See Annex I – To be completed nationally] Tacrolimus
Prograf in povezana imena (glejte Dodatek I) 1 mg trde kapsule [Glejte Dodatek I - Izpolni država članica] Takrolimus
[To be completed nationally]
49 [Izpolni država članica]
51 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
50 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
BLISTER FOIL 1 mg CAPSULES
PRETISNI OMOT 1 mg KAPSULE
52 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
51 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
ALUMINIUM WRAPPER 1 mg CAPSULES
ALUMINIJASTI OVITEK 1 mg KAPSULE
Prograf and associated names (see Annex I)1 mg hard capsules [See Annex I – To be completed nationally] Tacrolimus Oral use
Prograf in povezana imena (glejte Dodatek I) 1 mg trde kapsule [Glejte Dodatek I - Izpolni država članica] Takrolimus Peroralna uporaba.
CARTON 5 mg CAPSULES
ŠKATLA 5 mg KAPSULE
Prograf and associated names (see Annex I) 5 mg hard capsules [See Annex I – To be completed nationally] Tacrolimus
Prograf in povezana imena (glejte Dodatek I) 5 mg trde kapsule [Glejte Dodatek I - Izpolni država članica] Takrolimus
[To be completed nationally]
53 [Izpolni država članica]
55 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
54 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
BLISTER FOIL 5 mg CAPSULES
PRETISNI OMOT 5 mg KAPSULE
ALUMINIUM WRAPPER 5 mg CAPSULES
ALUMINIJASTI OVITEK 5 mg KAPSULE
Prograf and associated names (see Annex I) 5 mg hard capsules [See Annex I – To be completed nationally] Tacrolimus Oral use
Prograf in povezana imena (glejte Dodatek I) 5 mg trde kapsule [Glejte Dodatek I - Izpolni država članica] Takrolimus Peroralna uporaba.
57 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
56 PODATKI NA ZUNANJI OVOJNINI
CARTON 5 mg/ ml CONCENTRATE FOR SOLUTION FOR INFUSION
ŠKATLA 5 mg/ ml KONCENTRAT ZA RAZTOPINO ZA INFUNDIRANJE
Prograf and associated names (see Annex I) 5 mg/ ml concentrate for solution for infusion [See Annex I – to be completed nationally] Tacrolimus
Prograf in povezana imena (glejte Dodatek I) 5 mg/ 1 ml koncentrat za raztopino za infundiranje [Glejte Dodatek I - Izpolni država članica] Takrolimus
{MM/ YYYY} After reconstitution:
{MM/ LLLL} Po pripravi:
SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE
57 ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
59 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS AMPOULE LABEL 5 mg/ ml CONCENTRATE FOR SOLUTION FOR INFUSION
NALEPKA AMPULE 5 mg/ ml KONCENTRAT ZA RAZTOPINO ZA INFUNDIRANJE
Prograf and associated names (see Annex I) 5 mg/ ml concentrate for solution for infusion [See Annex I – to be completed nationally] Tacrolimus Intravenous use
Prograf in povezana imena (glejte Dodatek I) 5 mg/ 1 ml koncentrat za raztopino za infundiranje [Glejte Dodatek I - Izpolni država članica] Takrolimus Intravenska uporaba.
PACKAGE LEAFLET
60 NAVODILO ZA UPORABO
Prograf and associated names (see Annex I) 0.5 mg hard capsules Prograf and associated names (see Annex I) 1 mg hard capsules Prograf and associated names (see Annex I) 5 mg hard capsules
Prograf in povezana imena (glejte Dodatek I) 0, 5 mg trde kapsule Prograf in povezana imena (glejte Dodatek I) 1 mg trde kapsule Prograf in povezana imena (glejte Dodatek I) 5 mg trde kapsule [Glejte Dodatek I - Izpolni država članica] Takrolimus
What< Invented name > is and what it is used for 2.
Kaj je zdravilo < (Lastniško) ime zdravila > in za kaj ga uporabljamo 2.
Before you take< Invented name > 3.
Kaj morate vedeti, preden boste vzeli zdravilo < (Lastniško) ime zdravila > 3.
How to take< Invented name > 4.
Kako jemati zdravilo < (Lastniško) ime zdravila > 4.
How to store< Invented name > 6.
Shranjevanje zdravila < (Lastniško) ime zdravila > 6.
WHAT< INVENTED NAME > IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO < (LASTNIŠKO) IME ZDRAVILA > IN ZA KAJ GA UPORABLJAMO
< Invented name > belongs to a group of medicines called immunosuppressants.
< (Lastniško) ime zdravila > spada v skupino zdravil, ki jih imenujemo imunosupresivi.
Following your organ transplant (e. g. liver, kidney, heart), your body’ s immune system will try to reject the new organ .< Invented name > is used to control your body’s immune response enabling your body to accept the transplanted organ .< Invented name > is often used in combination with other medicines that also suppress the immune system.
Po presaditvi organa (npr. jeter, ledvic, srca) telo poskuša zavrniti novi organ. < (Lastniško) ime zdravila > uporabljamo za obvladovanje telesnega imunskega odziva, kar omogoči, da telo sprejme presajeni organ. < (Lastniško) ime zdravila > se pogosto uporablja v kombinaciji z drugimi zdravili, ki prav tako zavirajo imunski sistem.
You may also be given< Invented name > for an ongoing rejection of your transplanted liver, kidney, heart or other organ or if any previous treatment you were taking was unable to control this immune response after your transplantation.
< (Lastniško) ime zdravila > lahko dobite tudi zaradi dogajajoče se zavrnitve presajenih jeter, srca ali drugega organa, če zdravila, ki ste jih jemali pred tem, niso obvladala imunskega odziva po presaditvi.
BEFORE YOU TAKE< INVENTED NAME >
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO < (LASTNIŠKO) IME ZDRAVILA >
Do not take< Invented name >
Ne jemljite zdravila < (Lastniško) ime zdravila >
- If you are allergic (hypersensitive) to tacrolimus or any of the other ingredients of < Invented
- Če ste alergični na (preobčutljivi za) takrolimus ali katerokoli pomožno snov zdravila
name >.
< (Lastniško) ime zdravila >.
- If you are allergic (hypersensitive) to any antibiotic belonging to the subgroup of macrolide
- Če ste alergični na (preobčutljivi za) katerikoli antibiotik iz podskupine makrolidnih antibiotikov.
Take special care with< Invented name >
Bodite posebno pozorni pri jemanju zdravila < (Lastniško) ime zdravila >
- You will need to take< Invented name > every day as long as you need immunosuppression to
- < (Lastniško) ime zdravila > boste morali jemati vsak dan, dokler potrebujete imunosupresijo za
prevent rejection of your transplanted organ.
preprečitev zavrnitve presajenega organa.
- Whilst you are taking< Invented name > your doctor may want to carry out a number of tests (including
- Med jemanjem < (Lastniško) ime zdravila > vam bo zdravnik od časa do časa naredil različne
blood, urine, heart function, visual and neurological tests) from time to time.
preiskave (vključno s preiskavami krvi, urina, vida, delovanja srca in nevrološkimi preiskavami).
This is quite normal and will help your doctor to decide on the most appropriate dose of< Invented name > for you.
To je povsem običajno in bo zdravniku pomagalo, da izbere odmerek zdravila < (Lastniško) ime zdravila >, ki bo za vas najprimernejši.
John’ s wort (Hypericum perforatum) or any
- Ne jemljite nobenih zdravil rastlinskega izvora, npr. šentjanževke (Hypericum perforatum), in
other herbal products as this may affect the effectiveness and the dose of< Invented name > that you need to receive.
nobenih drugih izdelkov rastlinskega izvora, ker lahko vplivajo na učinkovitost in odmerek < (Lastniško) ime zdravila >, ki ga morate dobivati.
If in doubt please consult your doctor prior to taking any herbal products or remedies.
Če ste v dvomih, se pred uporabo kateregakoli izdelka ali zdravila rastlinskega izvoraposvetujte z zdravnikom.
- If you have liver problems or have had a disease which may have affected your liver, please tell
- Če imate težave z jetri ali ste kdaj imeli kakšno bolezen, ki bi lahko vplivala na jetra, morate to
your doctor as this may affect the dose of< Invented name > that you receive.
povedati zdravniku, ker lahko vpliva na vaš odmerek zdravila < (Lastniško) ime zdravila >.
- If you have diarrhoea for more than one day, please tell your doctor, because it might be
- Če imate drisko, ki traja več kot en dan, morate to povedati zdravniku, kajti potrebna utegne biti
necessary to adapt the dose of< Invented name > that you receive.
prilagoditev odmerka < (Lastniško) ime zdravila >, ki ga dobivate.
- In view of the potential risk of malignant skin changes with immunosuppressive therapy, you
- Imunosupresivno zdravljenje je povezano z možnim tveganjem za maligne spremembe na koži.
should wear appropriate protective clothing and use a sunscreen with a high sun protection factor to limit your exposure to sunlight and UV light.
Da boste omejili izpostavljenost sončni svetlobi in ultravijoličnim žarkom, morate nositi ustrezna zaščitna oblačila in uporabljati sredstvo za sončenje z visokim zaščitnim faktorjem.
Your doctor will
Zdravnik vam
advise you on the best course of action.
bo svetoval, kako je najbolje ravnati.
Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal remedies .< Invented name > blood levels can be affected by other medicines you take, and blood levels of other medicines can be affected by taking < Invented name > which may require and increase or decrease in < Invented name > dose.
Druga zdravila, ki jih jemljete, lahko vplivajo na koncentracijo zdravila < (Lastniško) ime zdravila > v krvi, pa tudi jemanje zdravila < (Lastniško) ime zdravila > lahko vpliva na koncentracijo drugih zdravil v krvi, zato utegne biti potrebno povečanje ali zmanjšanje odmerka < (Lastniško) ime zdravila >.
In particular, you should tell your doctor if you are taking or have recently taken medicines with active substances like:
Še zlasti morate zdravniku povedati, če jemljete ali ste v zadnjem času jemali zdravila, ki vsebujejo zdravilne učinkovine, kot so:
- antifungal medicines and antibiotics, particularly so-called macrolide antibiotics, used to treat
- protiglivična zdravila in antibiotiki, zlasti t. i. makrolidni antibiotiki, ki se uporabljajo za
infections e. g. ketoconazole, fluconazole, itraconazole, voriconazole, clotrimazole, erythromycin, clarithromycin, josamycin, and rifampicin
zdravljenje okužb, npr. ketokonazol, flukonazol, itrakonazol, vorikonazol, klotrimazol, eritromicin, klaritromicin, josamicin in rifampicin
- HIV protease inhibitors e. g ritonavir
- zaviralci proteaz HIV, npr. ritonavir
- the anti-ulcer substance omeprazole
- protiulkusna učinkovina omeprazol
- hormone treatments with ethinylestradiol (e. g the oral contraceptive pill) or danazol
- hormonska zdravljenja z etinilestradiolom (npr. kontracepcijske tablete) ali danazol
- medicines for high blood pressure or heart problems such as nifedipine, nicardipine, diltiazem
- zdravila za visok krvni tlak ali težave s srcem, npr. nifedipin, nikardipin, diltiazem in verapamil
and verapamil
- zdravila, ki jih imenujemo "statini" in se uporabljajo za zdravljenje zvišanega holesterola in
- medicines known as “ statins” used to treat elevated cholesterol and triglycerides
trigliceridov
- the anti-epileptic medicines phenytoin or phenobarbital
- antiepileptično zdravilo fenitoin ali fenobarbital
- the corticosteroids prednisolone and methylprednisolone
- kortikosteroida prednizolon in metilprednizolon
- the anti-depressant nefazodone
- antidepresiv nefazodon
John’ s Wort (hypericum perforatum)
- šentjanževka (Hypericum perforatum)
< Invented name > must not be taken with ciclosporin.
Zdravila < (Lastniško) ime zdravila > ne smete jemati skupaj s ciklosporinom.
Your doctor also needs to know if you are taking potassium supplements or potassium-sparing diuretics (e. g., amiloride, triamterene, or spironolactone), certain pain killers (so-called NSAIDs, e. g. ibuprofen), anticoagulants, or oral medication for diabetic treatment, while you take< Invented name >.
Zdravnik mora tudi vedeti, če med jemanjem < (Lastniško) ime zdravila > jemljete dodatke kalija, diuretike, ki ohranjajo kalij (npr. amilorid, triamteren ali spironolakton), določena zdravila proti bolečinam (t. i. nesteroidna protivnetna zdravila, npr. ibuprofen), antikoagulanse ali peroralna zdravila za diabetes.
The use of ibuprofen, amphotericin B, antivirals (e. g. aciclovir), may worsen kidney or nervous system problems when taken together with< Invented name >.
Če so ibuprofen, amfotericin B ali protivirusna zdravila (npr. aciklovir) uporabljeni hkrati z < (Lastniško) ime zdravila >, lahko poslabšajo težave z ledvicami ali živčevjem.
Taking< Invented name > with food and drink You should generally take < Invented name > on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal.
Jemanje zdravila < (Lastniško) ime zdravila > skupaj s hrano in pijačo Praviloma morate < (Lastniško) ime zdravila > vzeti na prazen želodec oz. vsaj 1 uro pred jedjo ali 2 do 3 ure po jedi.
Grapefruit and grapefruit juice should be avoided while taking< Invented name >.
Med jemanjem zdravila < (Lastniško) ime zdravila > se morate izogibati uživanju grenivk in pitju grenivkinega soka.
Pregnancy and breast-feeding If you plan to become pregnant or think that you may be pregnant, ask your doctor or pharmacist for advice before taking any medicine .< Invented name > is excreted into breast milk.
Nosečnost in dojenje Če nameravate zanositi ali mislite, da ste noseči, se posvetujte z zdravnikom ali s farmacevtom, preden vzamete katerokoli zdravilo. < (Lastniško) ime zdravila > se izloča v materinem mleku.
Therefore you should not breast-feed whilst receiving< Invented name >.
Zato med prejemanjem zdravila < (Lastniško) ime zdravila > ne smete dojiti.
63 Do not drive or use any tools or machines if you feel dizzy or sleepy, or have problems seeing clearly after taking< Invented name >.
62 Vpliv na sposobnost upravljanja vozil in strojev Če ste po uporabi < (Lastniško) ime zdravila > omotični, zaspani ali imate nejasen vid, ne upravljajte vozil ali strojev.
These effects are more frequently observed if< Invented name > is taken in conjunction with alcohol use.
Ti učinki so pogostejši, če je < (Lastniško) ime zdravila > uporabljen hkrati z alkoholom.
HOW TO TAKE< INVENTED NAME >
KAKO JEMATI ZDRAVILO < (LASTNIŠKO) IME ZDRAVILA >
Always take< Invented name > exactly as your doctor has told you.
Pri jemanju zdravila < (Lastniško) ime zdravila > natančno upoštevajte zdravnikova navodila.
The starting dose to prevent the rejection of your transplanted organ will be determined by your doctor calculated according to your body weight.
Začetni odmerki tik po presaditvi so praviloma
Initial doses just after transplantation will generally be in the range of 0.075 – 0.30 mg per kg body weight per day
od 0, 075 do 0, 30 mg na kg telesne mase na dan,
Your doctor will usually reduce your< Invented name > dose once your condition has stabilised.
Ko se bo vaše stanje ustalilo, bo zdravnik odmerek zdravila < (Lastniško) ime zdravila > ponavadi zmanjšal.
< Invented name > is taken orally twice daily, usually in the morning and evening.
< (Lastniško) ime zdravila > se zaužije dvakrat na dan, ponavadi zjutraj in zvečer.